Merck and BioNTech Extend Strategic Partnership
Accelerated Supply of Urgently Needed Lipids
Lipids are critical to the drug delivery system of mRNA therapies to the body for a vaccine to be effective. Only very few companies in the world are currently able to produce custom lipids in significant quantities and according to the highest quality requirements needed for vaccine production.
“What unites BioNTech and Merck is our strong belief in mRNA technology and our trustful collaboration in vaccine development. We are convinced that now is the time to pull together to supply as much vaccine as possible to the world. Extraordinary times like these require bold steps, and we are ready to take these steps to tackle one of the biggest challenges of humanity”, said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck.
With the outbreak of the pandemic, Merck and BioNTech had started to intensify their previously existing collaboration.
In the past weeks, Merck has been working hard to expand its already very high lipid production capacity. This required the further development of production technologies and the implementation of new, highly complex process steps. BioNTech and Merck are currently defining exact requirements and are aiming for a timely execution of their joint efforts.
Merck is a global leader in lipids. The company has extensive expertise in providing custom lipids and other critical components such as synthetic cholesterol for lipid nanoparticle formulations. Merck is active across multiple steps of the process flow and collaborates with many companies using lipid-based technologies to address Covid-19 vaccines and treatment.
Support of more than 50 vaccine projects worldwide
Since the outbreak of the pandemic, Merck has been intensely involved in the fight against the coronavirus. The Life Science business sector is supporting more than 50 vaccine projects worldwide with products and technologies. The company’s role is comparable to that of a supplier in the automotive sector. Depending on the project, Merck supports the research and development process, for which it offers raw materials and products such as proteases or antibodies. The company also offers a full spectrum of products used throughout the subsequent manufacturing processes for Covid-19 vaccines.
Because vaccine manufacturing is very complex and no standardized processes for innovative vaccines exist, Merck supports its customers in developing customized manufacturing platforms that enable industrial-scale production. Many Merck products are used for this purpose, for example single-use assemblies, systems for biopharmaceutical production and consumables.
Integrated offering across the mRNA value chain
With the acquisition of AmpTec, announced in early January, Merck has further strengthened its capabilities and capacities for the development and production of mRNA. In particular, the combination of AmpTec’s PCR-based mRNA technology with Merck’s extensive expertise in lipids manufacturing makes it possible to provide a truly integrated offering across the mRNA value chain.
In addition to vaccine development and production, Merck also supports more than 35 Covid-19 testing solutions and is collaborating with many clinical laboratories and diagnostics manufacturers. The company supplies critical raw materials across all key steps involved in diagnosing Covid-19 infections with PCR tests, such as oligonucleotide primers. In addition, it manufactures key products such as Hi-Flow membranes, for serologicals that enable testing for the presence of Covid-19 antibodies.
The Pfizer-BioNTech Covid-19 Vaccine (BNT162b2), which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer, and the marketing authorization holder is BioNTech in the United States, Europe, the United Kingdom, Canada, and other countries. It has been authorized for use by the health regulatory authorities of about 50 countries, including Switzerland and the European Union member states where it has been granted Conditional Marketing Authorization, and it has received authorizations for emergency use in e.g. the United Kingdom, the United States, and Canada. According to the data from the global Phase III clinical trial, the vaccine met all primary efficacy endpoints, demonstrating effectiveness of 95% in preventing Covid-19 in adults and 94% in adults over 65 years of age.
Other news from the department business & finance
Beckman Coulter and Fujirebio enter into partnership
The goal is a patient-friendly, blood-based Alzheimer's disease test
Merck Enters Two Strategic Collaborations to Strengthen AI-driven Drug Discovery
Partnerships with BenevolentAI and Exscientia to drive accelerated drug discovery with higher probability of success
Successful exit: adivo joins Zoetis
adivo’s team and platform will strengthen Zoetis’ capabilities in therapeutic antibody drug discovery for companion animals
Bertelsmann Investments acquires stake in AI-powered Israeli healthcare startup QuantHealth
AI-supported start-up company for clinical trial planning
Moderna and Immatics Announce Strategic Multi-Platform Collaboration
Develop Innovative Oncology Therapeutics
Microplate Dx secures £2.5 million to develop rapid diagnostic technology for better antibiotic use
In minutes rather than days to prescribe the optimal antibiotic
RIANA Therapeutics enters into collaboration agreement with LDC
"This cooperation has the great potential to lay the groundwork for new, urgently needed therapeutic approaches for AML patients"
Six companies enter BioInnovation Institute's Venture House program receiving additional financial support
AaviGen raises 17 million € in second financing round to advance precision gene therapies for heart failure towards the clinical stage
Life Science Factory to Open a New Location at Helmholtz Munich in 2024
Strategic partnership between Life Science Factory and Helmholtz Munich to promote spin-offs
Takara Bio and Eppendorf cooperate
Automation of Takara Bio’s Chemistries on Eppendorf’s Automated Pipetting Systems for Significantly Higher Efficiency
Mysthera Therapeutics Launches to Develop First-in-Class Autoimmune Disease Therapies
Seed Capital from Forty51 Ventures to Advance Pipeline of Pan-PIM Kinase Inhibitors
Valuable raw materials from olive waste
ETH spin-off Gaia Tech transforms waste from olive oil production into high-quality antioxidants for use in cosmetics or food
Qualifyze raises $12m to transform supply chain compliance in pharma by leveraging tech and audit data
KNAUER invests in Dresden-based start-up company
Both companies will offer integrated solutions in the field of material separation and laboratory organisation
Bruker Corporation and PhenomeX Inc. Announce Definitive Agreement for Bruker to Acquire PhenomeX in All-Cash Transaction
Acquisition initiates Bruker’s entry into functional single-cell biology research solutions
Most read news
Cells with an ear for music release insulin
For the first time, researchers are using music, including Queen's global hit "We will rock you," to stimulate insulin release from cells
"Anti-obesity drugs" normalises brain in obesity
Anti-obesity drug improves associative learning in people with obesity
Microbe of the Year 2023: Bacillus subtilis – for health and technology
Already, Bacillus subtilis is indispensable in many industries, and many more innovations are expected
Younger generation gets sick earlier and more often than older generation
In spite of their advanced age, they are in the middle of life, healthy, active and mentally alert – they are referred to as the “young old”
How sleep deprivation can harm the brain
Sleep deprivation decreases the amount of a factor that protects neurons
A whole new order of bacteria could hold the key to improving biogas production
The discovery was made by researchers from Germany, Spain and the Netherlands
How to inactivate common cold viruses
In the cold season, cold viruses are everywhere. But we can do something about it
How minimal genetic differences can turn healthy food into a deadly danger
You are what you eat - this old saying could take on a new dimension according to latest research results
New approach to testing for long Covid
Blood vessels in the eye altered with persistent coronavirus symptoms
More news from our other portals
Major breakthrough in the development of electric vehicle batteries
New study finds ways to suppress lithium plating in automotive batteries for faster charging electric vehicles
Blender Bites launches at Walmart USA
The products are to be introduced in about 1,600 stores across the country
Benchtop NMR spectroscopy can accurately analyse pyrolysis oils
More accessible analysis could help develop the potential of bio-oils as an alternative to fossil fuels
Green methanol for shipping and industry: € 10.4 Mio. for the "Leuna100" project
A consortium of two Fraunhofer institutes, DBI-Gastechnologisches Institut Freiberg, Technical University of Berlin and C1 makes industrial history at the Leuna site
Clean water from fog
A property known as photocatalytic memory ensures that this also functions when skies are overcast and at night
Green, sweet and crisp - New apple variety Pia41 approved
The apple bred at the Julius Kühn Institute receives variety protection
Research shows table salt could be the secret ingredient for better chemical recycling
Table salt as the key to the plastics recycling revolution?
Sugar: Small increase in production despite record prices
EU sugar market more than in need of reform to keep medium-sized processing companies competitive
Graphene discovery could help generate hydrogen cheaply and sustainably
Microscopic insights into electrochemical interfaces
Stanford study shows how the meat and dairy sector resists competition from alternative animal products
Scientists use quantum device to slow down simulated chemical reaction 100 billion times
What happens in femtoseconds in nature can now be observed in milliseconds in the lab
New battery holds promise for green energy
Redox-flow battery eliminates costly and inefficient membrane
Fondant under the magnifying glass
New insights into the properties of sweet coating: The results could be used to optimize the industrial production process in the future
Leipzig-based start-up converts CO₂ into green chemicals with patented plasma catalysis
CO₂ recycling as a useful complement to carbon capture and storage
A microchip for Parmigiano Reggiano cheese
Consorzio del Parmigiano Reggiano, p-Chip Corporation, and Kaasmerk Matec Partner to Launch Breakthrough in Food-Safe Digital Tracking Technology
Cleaning water with ‘smart rust’ and magnets
New method for pollutants such as crude oil, glyphosate, microplastics and hormones
A Second Life for Electric Car Batteries
Scientists develop a decision model for retired lithium-ion batteries